Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Clinical and Translational Oncology
Erschienen in: Clinical and Translational Oncology 10/2017

25.04.2017 | Research Article

Breast self-exam and patient interval associate with advanced breast cancer and treatment delay in Mexican women

verfasst von: E. Leon-Rodriguez, C. Molina-Calzada, M. M. Rivera-Franco, A. Campos-Castro

Erschienen in: Clinical and Translational Oncology | Ausgabe 10/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The objective of this study was to compare treatment intervals in breast cancer patients according to the detection method (breast self-exam vs screening).

Patients and methods

We conducted a retrospective analysis including 291 breast cancer patients at a Mexican tertiary referral hospital.

Results

Breast cancer detection method was mostly breast self-exam (60%). The median patient interval was 60.5 days, and was associated with marital status and socioeconomic level. Differences between the two groups were statistically significant for global interval, p = 0.002; however, health system interval was not statistically different.

Conclusion

In our country, breast cancer screening is opportunistic, with several weaknesses within its management and quality systems. Our study showed that even in specialized health care centers, breast cancer is detected by self-exam in up to 2/3 of patients, which can explain the advanced stages at diagnosis in our country. In developing countries, the immediate health care access for breast cancer patients should be prioritized as an initial step to reduce the global treatment initiation interval in order to reduce mortality.
Literatur
1.
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://​globocan.​iarc.​fr. Accessed 01 Oct 2016.
2.
Porter P. Westernizing women´s risk? Breast cancer in lower-income countries. N Engl J Med. 2008;358:213–6.CrossRefPubMed
3.
Weir HK, Thun MJ, Hankey BF, Ries LA, Howe HL, Wingo PA, et al. Annual report to the nation on the status of cancer, 1975–2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst. 2003;95:1276–99.CrossRefPubMed
4.
Sankaranarayanan R, Swaminathan R, Brenner H, Chen K, Chia KS, Chen JG, et al. Cancer survival in Africa, Asia, and Central America: a population-based study. Lancet Oncol. 2010;11:165–73.CrossRefPubMed
5.
Knaul FM, Nigenda G, Lozano R, Arreola-Ornelas H, Langer A, Frenk J. Cancer de mama en México: una prioridad apremiante. Salud Publica Mex 2009;51(suppl 2):S335–S344.
6.
Unger-Saldaña K. Challenges to the early diagnosis and treatment of breast cancer in developing countries. World J Clin Oncol. 2014;5(3):465–77.CrossRefPubMedPubMedCentral
7.
8.
Thomas DB, Gao DL, Ray RM, Wang WW, Allison CJ, Chen FL, et al. Randomized trial of breast self-examination in Shanghai: final results. J Natl Cancer Inst 2002;94(19):1445e57.
9.
Perry N, Broeders M, de Wolf C, Törnberg S, Holland R, von Karsa L. European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition–summary document. Ann Oncol. 2008; 19(4):614–22.
10.
Pack G, Gallo J. The culpability for delay in the treatment of cancer. Am J Cancer. 1938;33:443–62.
11.
Dobson CM, Russell AJ, Rubin GP. Patient delay in cancer diagnosis: what do we really mean and can we be more specific? BMC Health Services Res. 2014;14:387.CrossRef
12.
Ramirez AJ, Westcombe AM, Burgess CC, Sutton S, Littlejohns P, Richards MA. Factors predicting delayed presentation of symptomatic breast cancer: a systematic review. Lancet. 1999;353(9159):1127–31.CrossRefPubMed
13.
Richards MA, Smith P, Ramirez AJ, Fentiman IS, Rubens RD. The influence on survival of delay in the presentation and treatment of symptomatic breast cancer. Br J Cancer. 1999;79:858–64.CrossRefPubMedPubMedCentral
14.
Bright K, Barghash M, Donach M, de la Barrera MG, Schneider RJ, Formenti SC. The role of health system factors in delaying final diagnosis and treatment of breast cancer in Mexico City, Mexico. Breast. 2011;20(suppl 2):s54–9.CrossRefPubMed
15.
Unger-Saldaña, Miranda A, Zarco-Espinosa G, Mainero-Ratchelous F, Bargalló-Rocha E, Miguel Lázaro-León J. Health system delay and its effect on clinical stage of breast cancer: Multicenter study. Cancer. 2015;121(13):2198–206.
16.
Piñeros M, Sánchez R, Cendales R, Perry F, Ocampo R. Patient delay among Colombian women with breast cancer. Salud Publica Mex. 2009;51(5):372–80.CrossRefPubMed
17.
Odongo J, Makumbi T, Kalungid S, Galukande M. Patient delay factors in women presenting with breast cancer in a low income country. BMC Res Notes. 2015;8:467.CrossRefPubMedPubMedCentral
18.
Galukande M, Mirembe F, Wabinga H. Patient delay in accessing breast cancer care in a sub Saharan African Country: Uganda. Br J Med Med Res. 2014;4(13):2599–610.CrossRefPubMedPubMedCentral
19.
Arndt V, Sturmer T, Stegmaier C, Ziegler H, Dhom G, Brenner H. Patient delay and stage of diagnosis among breast cancer patients in Germany—a population based study. Br J Cancer. 2002;86(7):1034–40.CrossRefPubMedPubMedCentral
20.
Allgar VL, Neal RD. Delays in the diagnosis of 6 cancers: analysis of data from the National Survey of NHS Patients: cancer. Br J Cancer. 2005;92:1959–70.CrossRefPubMedPubMedCentral
21.
Mousa SM, Seifeldin IA, Hablas A, Elbana ES, Soliman AS. Patterns of seeking medical care among Egyptian breast cancer patients: relationship to late-stage presentation. Breast. 2011;20:555–61.CrossRefPubMedPubMedCentral
22.
Norsa’adah B, Rampal KG, Rahmah MA, Naing NN, Biswal BM. Diagnosis delay of breast cancer and its associated factors in Malaysian women [serial online]. BMC Cancer. 2011;11:141.
23.
Maghous A, Rais F, Ahid S, Benhmidou N, Bellahamou K, Loughlimi H, et al. Factors influencing diagnosis delay of advanced breast cancer in Moroccan women. BMC Cancer. 2016;16:356.CrossRefPubMedPubMedCentral
24.
López-Carrillo L, Torres-Sánchez L, López-Cervantes M, Rueda-Neria C. Identification of breast lesions in Mexico. Salud Publica Mex. 2001;43(3):199–202.CrossRefPubMed
25.
Uscanga-Sánchez S, Torres-Mejía G, Ángeles-Llerenas A, Domínguez-Malpica R, Lazcano-Ponce E. Breast cancer screening process indicators in Mexico: a case study. Salud Publica Mex. 2014;56(5):528–37.CrossRefPubMed
26.
Ma I, Dueck A, Gray R, Wasif N, Giurescu M, Lorans R, et al. Clinical and self breast examination remain important in the era of modern screening. Ann Surg Oncol. 2012;19(5):1484–90.CrossRefPubMed
27.
Kösters JP, Gøtzsche PC. Regular self-examination or clinical examination for early detection of breast cancer. Cochrane Database Syst Rev. 2003;2. Art. No. CD003373.
28.
29.
Martínez-Montañez OG, Uribe-Zúñiga P, Hernández-Avila M. Public policies for breast cancer detection in Mexico. Salud Publica Mex. 2009; 51(Supl 2):s350–s360.
30.
Unger-Saldaña K, Infante-Castañeda CB. Breast cancer delay: a grounded model of help-seeking behaviour. Soc Sci Med. 2011;72(7):1096–104.CrossRefPubMed
Metadaten
Titel
Breast self-exam and patient interval associate with advanced breast cancer and treatment delay in Mexican women
verfasst von
E. Leon-Rodriguez
C. Molina-Calzada
M. M. Rivera-Franco
A. Campos-Castro
Publikationsdatum
25.04.2017
Verlag
Springer International Publishing
Erschienen in
Clinical and Translational Oncology / Ausgabe 10/2017
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-017-1666-6

Weitere Artikel der Ausgabe 10/2017

Clinical and Translational Oncology 10/2017 Zur Ausgabe

Review article

Neoadjuvant treatment for borderline and resectable pancreatic ductal adenocarcinoma

Research Article

Correlation of preoperative ROMA scores with clinical stage in epithelial ovarian cancer patients

Review Article

Diagnosis and staging of pancreatic ductal adenocarcinoma

Research Article

Diagnostic value of the dual-luciferase report assay for predicting response to glucocorticoid in children with acute lymphoblastic leukemia

Research Article

Age-based disparities in the use of total thyroidectomy for papillary thyroid carcinoma

Research Article

Micropapillary bladder cancer: a clinico-pathological characterization and treatment analysis

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise